|
|||||
|
|
The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials |
|
| Authors: | Arabi Seyyed Mostafa Chambari Mahla Malek-Ahmadi Mahsa Bahrami Leila Sadat Hadi Vahid Rizzo Manfredi Sahebkar Amirhossein |
| Affiliation: | 1.Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran ;2.Department of Basic Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran ;3.Department of Nutrition and Biochemistry, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran ;4.Metabolic Syndrome Research Center, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran ;5.Department of Nutrition Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran ;6.Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran ;7.Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran ;8.Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy ;9.Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ;10.Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran ;11.School of Medicine, The University of Western Australia, Perth, Australia ;12.Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran ; |
| Abstract: | Background Previous studies have reported that statin or ezetimibe therapy has an anti-inflammatory effect. However, the results of individual studies on the effect of statin therapy in combination with ezetimibe on C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels have not been clear. Therefore, the present systematic review and meta-analysis were conducted on randomized clinical trials (RCTs) to evaluate the effect of statin therapy in combination with ezetimibe on CRP and hs-CRP levels. MethodsA literature search was carried out on the MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases up to February 2022 to find eligible studies. The pooled effect sizes were considered for weighted mean difference (WMD) and 95% confidence intervals (CI) for CRP and hs-CRP, and it was also determined as standardized weighted mean difference (SMD) for overall CRP. For all variables, a random-effects model was used. ResultsOf the 57 studies included in the systematic review, 53 were used for meta-analysis. Statin therapy in combination with ezetimibe significantly reduced the serum levels of hs-CRP (WMD ??0.2 mg/l; 95% CI ??0.4, ??0.1, P???0.001) and overall CRP (SMD ??0.16 mg/l; 95% CI ??0.2, ??0.07, P???0.001). Nevertheless, CRP levels were not significantly changed by combination therapy. A significant association was observed between the serum low-density lipoprotein cholesterol (LDL-C) changes and hs-CRP levels, which can justify the source of heterogeneity. ConclusionsThe current study showed that statin therapy in combination with ezetimibe could be effective in reducing the levels of hs-CRP and overall CRP. Graphical abstract |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |